Rosen N - Search Results

1

Development of purine-scaffold small molecule inhibitors of Hsp90.

Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Chiosis G, et al. Among authors: rosen n. Curr Cancer Drug Targets. 2003 Oct;3(5):371-6. doi: 10.2174/1568009033481778. Curr Cancer Drug Targets. 2003. PMID: 14529388 Review.

2

Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90.

Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N, Hartl FU. Schneider C, et al. Among authors: rosen n. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14536-41. doi: 10.1073/pnas.93.25.14536. Proc Natl Acad Sci U S A. 1996. PMID: 8962087 Free PMC article.

3

Synthesis and evaluation of geldanamycin-estradiol hybrids.

Kuduk SD, Zheng FF, Sepp-Lorenzino L, Rosen N, Danishefsky SJ. Kuduk SD, et al. Among authors: rosen n. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. doi: 10.1016/s0960-894x(99)00185-7. Bioorg Med Chem Lett. 1999. PMID: 10340605

4

Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.

Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. Zheng FF, et al. Among authors: rosen n. Cancer Res. 2000 Apr 15;60(8):2090-4. Cancer Res. 2000. PMID: 10786665

5

Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.

Srethapakdi M, Liu F, Tavorath R, Rosen N. Srethapakdi M, et al. Among authors: rosen n. Cancer Res. 2000 Jul 15;60(14):3940-6. Cancer Res. 2000. PMID: 10919672

6

LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family.

Chiosis G, Rosen N, Sepp-Lorenzino L. Chiosis G, et al. Among authors: rosen n. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. doi: 10.1016/s0960-894x(01)00099-3. Bioorg Med Chem Lett. 2001. PMID: 11294389

7

A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.

Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. Chiosis G, et al. Among authors: rosen n. Chem Biol. 2001 Mar;8(3):289-99. doi: 10.1016/s1074-5521(01)00015-1. Chem Biol. 2001. PMID: 11306353

8

Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.

Münster PN, Srethapakdi M, Moasser MM, Rosen N. Münster PN, et al. Among authors: rosen n. Cancer Res. 2001 Apr 1;61(7):2945-52. Cancer Res. 2001. PMID: 11306472

9

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.

Münster PN, Basso A, Solit D, Norton L, Rosen N. Münster PN, et al. Among authors: rosen n. Clin Cancer Res. 2001 Aug;7(8):2228-36. Clin Cancer Res. 2001. PMID: 11489796

10

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

Moasser MM, Basso A, Averbuch SD, Rosen N. Moasser MM, et al. Among authors: rosen n. Cancer Res. 2001 Oct 1;61(19):7184-8. Cancer Res. 2001. PMID: 11585753

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

721 results

Search Page